Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

March 30, 2022

Conditions
HistoplasmosisAIDS
Interventions
DRUG

single dose of L-AmB

(i) single IV dose of 10 mg/kg of L-AmB on day 1;

DRUG

2 doses of L-AmB

(ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;

DRUG

2 weeks of L-AmB

(iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.

Trial Locations (1)

90020-090

Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre

All Listed Sponsors
collaborator

Hospital de Clinicas de Porto Alegre

OTHER

collaborator

Hospital Nossa Senhora da Conceicao

OTHER

collaborator

Irmandade Santa Casa de Misericórdia de Porto Alegre

OTHER

lead

Alessandro Pasqualotto

OTHER

NCT04059770 - Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients | Biotech Hunter | Biotech Hunter